Quantum Genesis AI Corp.

corporate_fare Company Profile

Quantum Genesis AI Corp.

QTZM·OTC·Industrial Applications And Services·CIK 0001663038

Quantumzyme Corp. is a biotransformation company focused on clean and green chemistry, specifically developing engineered enzymes for active pharmaceutical ingredient ("API") production. The company conducts research to enhance enzyme activity, selectivity, and specificity using novel quantum mechanics, molecular modeling, and engineering approaches. Quantumzyme aims to simplify complex chemistry and reduce production steps for chemical companies. The company has engineered its first product, an enzyme for use in pharmaceutical API production of Ibuprofen, specifically targeting pharmaceutical companies that produce generic drugs. Quantumzyme is currently identifying third-party manufacturers and distributors for large-scale manufacturing and distribution of this product. As of the date of this report, the company has not filed for patent protection for this product and does not anticipate doing so in the near future, as the associated costs currently outweigh the anticipated benefits.

Quantum Genesis AI Corp. (OTC:QTZM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 5 items for QTZM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-11, rated 9/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for QTZM spans 10-Q, 10-K/A, 8-K, DEF 14C.

Recent high-impact activity:

Quantum Genesis AI Reports $59 Cash, $4.4M Net Loss Driven by Debt Conversion, and Critical Going Concern Warning (2026-06-11)
Quantum Genesis AI Corp. Secures Key Ibuprofen Enzyme Patent from CEO (2026-04-15)
Quantum Genesis AI Corp. Reports Near-Zero Cash, Going Concern Warning, and $4.3M Loss from Debt Conversion (2026-03-19)
Quantumzyme Corp. Finalizes Rebranding to Quantum Genesis AI Corp., New Symbol QGAI (2026-02-13)
Quantumzyme Corp. to Rebrand as Quantum Genesis AI Corp., Signaling Strategic Shift (2026-01-15)

Browse all tickers starting with Q →

show_chartPrice Chart

Loading chart...

feed QTZM - Latest Insights

Filing Type

Date Range

QTZM

Jun 11, 2026, 4:25 PM EDT

Filing Type: 10-Q

Importance Score:

Quantum Genesis AI Reports $59 Cash, $4.4M Net Loss Driven by Debt Conversion, and Critical Going Concern Warning

Price at Filing: $0.350

Real-time Price: $0.350

Change: $0 (0%)

Market Cap: $14.34M

Sentiment: Negative

View Wiseek Article

QTZM

Apr 15, 2026, 1:44 PM EDT

Filing Type: 10-K/A

Importance Score:

Quantum Genesis AI Corp. Secures Key Ibuprofen Enzyme Patent from CEO

Price at Filing: $0.350

Real-time Price: $0.350

Change: $0 (0%)

Market Cap: $14.34M

Sentiment: Positive

View Wiseek Article

QTZM

Mar 19, 2026, 3:15 PM EDT

Filing Type: 10-Q

Importance Score:

Quantum Genesis AI Corp. Reports Near-Zero Cash, Going Concern Warning, and $4.3M Loss from Debt Conversion

Price at Filing: $0.350

Real-time Price: $0.350

Change: $0 (0%)

Market Cap: $14.34M

Sentiment: Negative

View Wiseek Article

QTZM

Feb 13, 2026, 5:20 PM EST

Filing Type: 8-K

Importance Score:

Quantumzyme Corp. Finalizes Rebranding to Quantum Genesis AI Corp., New Symbol QGAI

Price at Filing: $0.350

Real-time Price: $0.350

Change: $0 (0%)

Market Cap: $14.34M

Sentiment: Positive

View Wiseek Article

QTZM

Jan 15, 2026, 4:05 PM EST

Filing Type: DEF 14C

Importance Score:

Quantumzyme Corp. to Rebrand as Quantum Genesis AI Corp., Signaling Strategic Shift

Price at Filing: $2.19

Real-time Price: $0.350

Change: -$1.84 (-84%)

Market Cap: $14.34M

Sentiment: Neutral

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile